ATE360000T1 - Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung - Google Patents

Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Info

Publication number: ATE360000T1
Authority: AT; Austria
Prior art keywords: dihydroxy; vitamin; alpha; sub; oxime
Prior art date: 2001-10-12

Application number

AT02767010T

Other languages

English (en)

Inventor

Gary H Posner

Jay A White

Glenville Jones

Bethany Halford

Mehmet Kahraman

Heung Bae Jeon

Original Assignee

Univ Johns Hopkins

Cytochroma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-12

Filing date

2002-10-11

Publication date

2007-05-15

2002-10-11 Application filed by Univ Johns Hopkins, Cytochroma Inc filed Critical Univ Johns Hopkins

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE360000T1 publication Critical patent/ATE360000T1/de

Links

-1 OXIME ANALOGUE OF 1-ALPHA,25-DIHYDROXY-VITAMIN-D3 Chemical class 0.000 title 1
230000000125 calcaemic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 abstract 1
101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Dermatology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02767010T 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung ATE360000T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32842801P	2001-10-12	2001-10-12

Publications (1)

Publication Number	Publication Date
ATE360000T1 true ATE360000T1 (de)	2007-05-15

Family

ID=23280940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02767010T ATE360000T1 (de)	2001-10-12	2002-10-11	Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Country Status (11)

Country	Link
US (1)	US6982258B2 (de)
EP (1)	EP1436257B1 (de)
JP (1)	JP4436674B2 (de)
AT (1)	ATE360000T1 (de)
CA (1)	CA2463505C (de)
CY (1)	CY1106638T1 (de)
DE (1)	DE60219655T2 (de)
DK (1)	DK1436257T3 (de)
ES (1)	ES2283593T3 (de)
PT (1)	PT1436257E (de)
WO (1)	WO2003031400A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6242434B1 (en)	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
IL153378A0 (en)	2000-07-18	2003-07-06	Bone Care Internat Inc	STABILIZED 1alpha-HYDROXY VITAMIN D
US20050059641A1 (en) *	2003-06-17	2005-03-17	Aphios Corporation	Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) *	2003-07-30	2005-09-01	Jin Tian	Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005110435A1 (en) *	2004-05-10	2005-11-24	Novacea, Inc.	Prevention of arterial restenosis with active vitamin d compounds
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006032299A1 (en) *	2004-09-24	2006-03-30	Susanna Miettinen	Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) *	2005-01-04	2006-07-13	Johns Hopkins University	HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
WO2006113990A2 (en) *	2005-04-25	2006-11-02	Cytochroma Inc.	LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
US20070122477A1 (en) *	2005-10-12	2007-05-31	Cytochroma, Inc.	Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
CA2882048C (en)	2006-02-03	2020-03-24	Opko Renal, Llc	Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu)	2006-06-21	2018-08-28	Opko Ireland Global Holdings Ltd	Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
JP2010524973A (ja) *	2007-04-18	2010-07-22	ジョンズホプキンスユニバーシティ	カルシトリオールの低カルシウム血性、高抗増殖性類似体
CA2683514C (en)	2007-04-25	2019-07-09	Proventiv Therapeutics, Llc	Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CA2684778C (en) *	2007-04-25	2017-09-05	Cytochroma Inc.	Methods and compounds for vitamin d therapy
ES2401205T3 (es) *	2007-04-25	2013-04-17	Cytochroma Inc.	Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
WO2009047644A2 (en) *	2007-04-25	2009-04-16	Cytochroma Inc.	Method of treating vitamin d insufficiency and deficiency
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en)	2008-03-25	2012-08-08	Univ Maryland	C-17 heteroaryl steroidal CYP17 inhibitors
KR101685031B1 (ko)	2008-04-02	2016-12-09	사이토크로마 인코포레이티드	비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
WO2010091306A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100227414A1 (en) *	2009-03-05	2010-09-09	Trex Enterprises Corp.	Affinity capture mass spectroscopy with a porous silicon biosensor
WO2011088209A2 (en)	2010-01-13	2011-07-21	Cytochroma Inc.	1-deoxy analogs of vitamin d-related compounds
CN103037902A (zh)	2010-03-29	2013-04-10	赛特克罗公司	用于降低甲状旁腺水平的方法和组合物
EP2968370A4 (de)	2013-03-14	2016-09-21	Univ Maryland	Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
EP3033088A4 (de)	2013-08-12	2017-03-08	Tokai Pharmaceuticals, Inc.	Biomarker zur behandlung neoplastischer störungen mit androgen-anzielenden therapien
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) *	2015-01-13	2016-07-06	南京理工大学	维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) *	2015-06-09	2016-08-24	南京理工大学	一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
EP4596045A3 (de)	2016-03-28	2025-10-15	EirGen Pharma Ltd.	Verfahren zur behandlung von vitamin d
CN117003679A (zh) *	2022-04-29	2023-11-07	南澳大利亚大学	新型抑制剂化合物
WO2025094144A1 (en)	2023-11-02	2025-05-08	Eirgen Pharma Ltd.	Controlling loss of kidney function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4481198A (en) *	1984-02-13	1984-11-06	Wisconsin Alumni Research Foundation	Vitamin D metabolism inhibitor
GB9623569D0 (en) *	1996-11-13	1997-01-08	Immunodiagnostic Systems Ltd	Vitamin D immumoassay systems

2002
- 2002-10-11 PT PT02767010T patent/PT1436257E/pt unknown
- 2002-10-11 DE DE60219655T patent/DE60219655T2/de not_active Expired - Lifetime
- 2002-10-11 AT AT02767010T patent/ATE360000T1/de active
- 2002-10-11 WO PCT/CA2002/001519 patent/WO2003031400A1/en not_active Ceased
- 2002-10-11 EP EP02767010A patent/EP1436257B1/de not_active Expired - Lifetime
- 2002-10-11 ES ES02767010T patent/ES2283593T3/es not_active Expired - Lifetime
- 2002-10-11 DK DK02767010T patent/DK1436257T3/da active
- 2002-10-11 JP JP2003534384A patent/JP4436674B2/ja not_active Expired - Fee Related
- 2002-10-11 CA CA2463505A patent/CA2463505C/en not_active Expired - Lifetime
- 2002-10-15 US US10/270,158 patent/US6982258B2/en not_active Expired - Lifetime
2007
- 2007-06-04 CY CY20071100741T patent/CY1106638T1/el unknown

Also Published As

Publication number	Publication date
DE60219655D1 (de)	2007-05-31
EP1436257B1 (de)	2007-04-18
US20030171342A1 (en)	2003-09-11
CA2463505A1 (en)	2003-04-17
WO2003031400A1 (en)	2003-04-17
JP4436674B2 (ja)	2010-03-24
CA2463505C (en)	2011-07-12
EP1436257A1 (de)	2004-07-14
ES2283593T3 (es)	2007-11-01
DK1436257T3 (da)	2007-06-25
DE60219655T2 (de)	2007-12-27
CY1106638T1 (el)	2012-01-25
US6982258B2 (en)	2006-01-03
PT1436257E (pt)	2007-05-31
JP2005536444A (ja)	2005-12-02

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1436257

Country of ref document: EP

Publication	Publication Date	Title
DE60219655D1 (de)	2007-05-31	Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
AR026173A1 (es)	2003-01-29	Inhibidores de neuraminidasas.
ES2139943T3 (es)	2000-02-16	Nuevos inhibidores de la sintasa de prostaglandina.
NO20031687D0 (no)	2003-04-11	Veksthormonsekretagoger
DK1474406T3 (da)	2007-07-23	Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
BRPI0410081A (pt)	2006-05-16	composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
ATE232873T1 (de)	2003-03-15	Phosphonsaürederivate als ptp-1b-inhibitoren
CO4910163A1 (es)	2000-04-24	Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
BRPI0415288A (pt)	2006-12-19	composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
DK0705254T3 (da)	1999-01-25	Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
ES2184070T3 (es)	2003-04-01	Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
BRPI0410117A (pt)	2006-05-23	composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
SE0101675D0 (sv)	2001-05-11	Novel composition
NO20024528D0 (no)	2002-09-20	Proteaseinhibitorer
AU2003233735A8 (en)	2003-12-31	24-sulfoximine vitamin d3 compounds
FR2757857B1 (fr)	1999-04-23	Diselenures et selenosulfures aromatiques, leur preparation et leurs utilisations, notamment therapeutiques
BR0209128A (pt)	2005-11-01	Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
ATE281432T1 (de)	2004-11-15	C-16 ungesätigte fp-selektive prostaglandin analoge
ATE238986T1 (de)	2003-05-15	1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
WO2004054968A3 (en)	2004-10-21	25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
DE60001433D1 (de)	2003-03-27	Alpha, beta-ungesättigte Ketone
NO20050612L (no)	2005-02-03	Pyrrolidinderivater som oksytocinantagonister
NO983511D0 (no)	1998-07-30	Difenylstilbener som pro-legemidler for COX-2-inhibitorer
NO20050270L (no)	2005-01-17	Nye forbindelser, deres anvendelse og fremstilling